Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Enanta pharmaceuticals - You Need To See This

Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpatient adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the elderly and/or those with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) or…

Recap Of Friday's Biotech Catalysts - End of The Day Summary

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analyst Ratings for Enanta Pharmaceuticals

Within the last quarter, Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings:

Enanta Pharmaceuticals's Return On Capital Employed Overview

Benzinga Pro data, Enanta Pharmaceuticals (NASDAQ:ENTA) reported Q2 sales of $18.72 million. Earnings fell to a loss of $33.59 million, resulting in a 11.55% decrease from last quarter.

Expert Ratings for Enanta Pharmaceuticals

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint

Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial Virus (RSV).

What 4 Analyst Ratings Have To Say About Enanta Pharmaceuticals

What 4 Analyst Ratings Have To Say About Enanta Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Enanta Pharmaceuticals (NASDAQ:ENTA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Where Enanta Pharmaceuticals Stands With Analysts

Where Enanta Pharmaceuticals Stands With Analysts

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:

Enanta Pharmaceuticals: Q1 Earnings Insights

Enanta Pharmaceuticals: Q1 Earnings Insights

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q1 earnings results on Tuesday, February 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

1

Organisations

European Commission

B of A Securities

Coinbase Global

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

396,146 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play